Gina Mauro

January 21, 2023

Zolbetuximab plus mFOLFOX6 lengthened the time to progression for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.

January 21, 2022

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.

December 15, 2021

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

December 08, 2021

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

June 09, 2021

Treatment with the study drug was associated with a doubling of a survival outcome in patients with advanced gastrointestinal stromal tumor, compared to placebo.

June 08, 2021

More than six years of follow-up data show that Opdivo alone, or in combination with Yervoy, continued to induce long-term survival benefits compared to Yervoy alone in patients with previously untreated advanced skin cancer.

June 07, 2021

The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.

June 04, 2021

Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.

December 17, 2020

Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

December 11, 2020

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.